Twist Bioscience (NASDAQ:TWST) Trading Up 5.4%

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report)'s stock price traded up 5.4% on Tuesday . The company traded as high as $39.28 and last traded at $39.28. 407,370 shares changed hands during trading, a decline of 60% from the average session volume of 1,010,725 shares. The stock had previously closed at $37.26.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. TD Cowen upped their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, June 13th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Guggenheim started coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a "buy" rating and a $53.00 price target on the stock. Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th. Finally, Robert W. Baird upped their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $48.22.

Twist Bioscience Price Performance

The firm has a 50-day simple moving average of $47.98 and a 200-day simple moving average of $42.65. The firm has a market capitalization of $2.39 billion, a PE ratio of -11.81 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to analysts' expectations of $77.40 million. During the same period in the previous year, the business posted ($1.01) EPS. The business's quarterly revenue was up 27.7% compared to the same quarter last year. Equities analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the transaction, the chief executive officer now directly owns 499,593 shares in the company, valued at $19,948,748.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $205,200.27. Following the transaction, the chief executive officer now owns 499,593 shares of the company's stock, valued at $19,948,748.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,732 shares of the company's stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $49.41, for a total transaction of $85,578.12. Following the completion of the transaction, the chief executive officer now owns 505,846 shares of the company's stock, valued at $24,993,850.86. The disclosure for this sale can be found here. Insiders sold 17,483 shares of company stock worth $781,448 in the last three months. Corporate insiders own 3.92% of the company's stock.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the business. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. raised its position in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience in the second quarter worth $61,000. Nisa Investment Advisors LLC boosted its position in shares of Twist Bioscience by 31.3% during the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company's stock worth $113,000 after acquiring an additional 546 shares during the last quarter. Finally, CWM LLC grew its stake in Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company's stock valued at $120,000 after acquiring an additional 524 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.